Funding & Disinvestments
-
Sanofi acquires global rights to Sino Biopharmaceutical’s Anxu in USD1.53B deal
The agreement includes a USD135 million upfront payment to Sino Biopharmaceutical for worldwide rights, with up to USD1.39 billion in potential milestone payments based on development, regulatory approvals, and sales.
-
UCB secures USD1.1 B global rights for Antengene’s next-generation autoimmune therapy
ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.
-
Arctic Vision expands ophthalmic capabilities through strategic MDCO Technology acquisition
The acquisition encompasses MDCO’s complete portfolio of ophthalmic devices, including intraocular lenses (IOL), implantable contact lenses (Phakic Lens), and various refractive device platforms.
-
Oman’s Khazaen Economic City attracts USD39M in pharmaceutical investment to boost domestic medicine production
The company plans to develop the first phase of this facility on a 10,000 square metre site with an initial investment of RO 15 million (USD39 million).
-
Mercy Ships wraps up 2025 mission in Madagascar
This mission represented Mercy Ships’ fifth visit to Madagascar since 1996 and the second consecutive field service of the Africa Mercy in the port city of Tamatave.
-
Merck KGaA enters USD3B AI drug discovery partnership with Valo Health to target Parkinson’s disease
Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.